ImmunityBio (NASDAQ:IBRX) Trading Down 6.9% - Here's Why

Key Points

• Shares fell 6.9% after the FDA issued a warning letter over allegedly misleading promotional claims for Anktiva, sparking securities‑fraud lawsuits and heightened regulatory and commercialization risk.
• ImmunityBio secured $100 million of financing, including $75 million of non‑dilutive royalty financing, which improves near‑term liquidity and reduces immediate dilution pressure.
• Analysts remain largely positive (consensus "Moderate Buy" with an average target of $14.40), even as recent insider selling and sizable institutional buying create mixed signals for investors.

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report)'s share price was down 6.9% during trading on Wednesday . The company traded as low as $7.01 and last traded at $7.14. Approximately 19,330,790 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 38,808,844 shares. The stock had previously closed at $7.67.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio secured $100 million of financing (including $75 million of non‑dilutive royalty financing) to support global expansion and pipeline advancement — improves near‑term liquidity and reduces immediate dilution risk. ImmunityBio Strengthens Balance Sheet with $100 Million of Financing
• Positive Sentiment: High‑profile media commentary has been supportive: Jim Cramer publicly suggested investors may consider owning IBRX as a speculative position, which can attract retail interest and short‑term buying. Jim Cramer on ImmunityBio
• Neutral Sentiment: Analysts and market writeups note recent volatility and strong quarterly performance metrics, prompting debate on whether the stock merits reassessment after rapid swings. These pieces provide context but are less likely to move price than regulatory/legal headlines. ImmunityBio Rallies as Firm Raises $100M
• Negative Sentiment: The FDA sent a warning letter saying promotional claims about ImmunityBio’s lead biologic (Anktiva) were misleading; that finding sparked a sharp earlier selloff and is the core catalyst for today’s decline as investors reassess regulatory and commercialization risk. ImmunityBio Receives FDA Warning Letter
• Negative Sentiment: Multiple securities‑fraud class actions and investor‑notification filings have been announced (several law firms seeking lead plaintiffs, deadlines in late May), increasing potential legal exposure, uncertainty over damages, and ongoing headline risk that is pressuring the stock. ImmunityBio Sued After FDA Flags Misleading Cancer Claims

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Jefferies Financial Group raised their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the company a "buy" rating in a report on Friday, December 12th. Weiss Ratings reissued a "sell (e+)" rating on shares of ImmunityBio in a research report on Monday, December 29th. BTIG Research started coverage on shares of ImmunityBio in a research note on Thursday, March 12th. They issued a "buy" rating and a $13.00 target price for the company. HC Wainwright lifted their price target on shares of ImmunityBio from $10.00 to $15.00 and gave the stock a "buy" rating in a report on Monday, February 23rd. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $23.00 price target on shares of ImmunityBio in a research report on Monday, March 23rd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.40.

ImmunityBio Stock Down 6.9%

The firm has a market cap of $7.34 billion, a PE ratio of -18.79 and a beta of -0.03. The stock has a 50 day moving average price of $7.72 and a two-hundred day moving average price of $4.31.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. As a group, equities analysts anticipate that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Christobel Selecky sold 50,000 shares of the company's stock in a transaction on Friday, January 16th. The stock was sold at an average price of $5.00, for a total value of $250,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Barry J. Simon sold 165,000 shares of the firm's stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares of the company's stock, valued at $29,989,665.25. This trade represents a 5.34% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 501,967 shares of company stock valued at $4,466,412. Corporate insiders own 69.48% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Armistice Capital LLC acquired a new stake in shares of ImmunityBio during the second quarter worth about $20,497,000. Heights Capital Management Inc. purchased a new position in ImmunityBio during the 3rd quarter worth approximately $16,152,000. Vanguard Group Inc. raised its position in ImmunityBio by 26.8% during the 3rd quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company's stock worth $68,032,000 after buying an additional 5,837,898 shares during the last quarter. State Street Corp lifted its stake in ImmunityBio by 45.4% during the 4th quarter. State Street Corp now owns 16,455,703 shares of the company's stock valued at $32,582,000 after acquiring an additional 5,139,890 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of ImmunityBio by 439.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company's stock valued at $12,182,000 after acquiring an additional 5,012,001 shares during the last quarter. 8.58% of the stock is owned by institutional investors and hedge funds.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.